STAT6 being a major component of the IL-4 receptor signaling pathway, this result was corroborated by the significantly reduced CLL cells proliferation found in the absence of IL-4 in the stimulatory cocktails, or when a selective JAK3 inhibitor (PF-956980) was used (Fig. 6B). This evidence concerns the gene IL4 and B-cell chronic lymphocytic leukemia.